Clinical trials: Lung Cancer Patient
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer
This phase Ib trial studies the safety and best dose of binimetinib when given in combination with docetaxel in treating patients with previously treated, stage IV non-small cell lung cancer.
- Trial name
- NCT02451865
- Testing
- Binimetinib, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Complication,Postoperative, Lung Cancer
Relationship Between Hand Dynamometer Measurements, PFT, and mFI With Postoperative Outcomes
The study will take place at SBÜ Ankara Atatürk Sanatorium Training and Research Hospital and will include 100 patients over the age of 40 who are scheduled for lung malignancy surgery after 01 April 2024.
- Trial name
- NCT06338007
- Testing
- Hand Dynamometer, Pulmonary Function Test, Modified Frailty Index
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Atatürk Chest Diseases and Chest Surgery Training and Research Hospital
Inoperable Non Small Cell Lung Cancer
Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer
To determine the safety of Alimta when used with chemoradiation in inoperable non small cell lung cancer
- Trial name
- NCT00330044
- Testing
- Premetrexed (Alimta), Carboplatin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Non-small Cell Lung Cancer, Breast Cancer
Copenhagen Master Observational Trial
The primary objectives of this prospective non-interventional study (NIS) are to assess and describe outcomes in relation to biomarkers, including whole-genome sequencing (WGS) in patients with non- small cell lung cancer (NSCLC)…
- Trial name
- C-MOT (NCT05145244)
- Testing
- No Intervention: Observational Cohort
- Where
- Denmark
- Volunteers
- 2,400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Obstetric Complication, Gynecologic Cancer
Lung Ultrasound in Critically Ill Obstetrics and Gynecological Patients
Pulmonary dysfunction aggravates the illness of critically ill obstetrics and gynecological patients. Early identification with bedside technique and prompt management may improve the outcome of critical care in this vulnerable…
- Conditions
- Obstetric Complication, Gynecologic Cancer, Lung Diseases, Ultrasound
- Trial name
- POLUS (NCT06728709)
- Testing
- ultrasound detection of any abnormal ultrasonographical findings.
- Where
- Egypt
- Volunteers
- 280 people
- Sponsor
- Ain Shams University
Extensive-Stage Small Cell Lung Cancer
Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung Cancer
This is an investigator-initiated, single-center, observational, noninterventional retrospective real-world cohort study evaluating the effectiveness and safety of tarlatamab as second-line or later-line therapy in Chinese adults…
- Trial name
- NCT07885332
- Testing
- Tarlatamab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Ruijin Hospital
Lung Cancer, Atrial Fibrillation
PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer
The aim of this study is to assess whether prophylactic treatment with metoprolol or losartan is able to reduce the incidence of atrial fibrillation (AF) in patients undergoing thoracic surgery for lung cancer, showing elevated…
- Trial name
- PRESAGE (NCT01281787)
- Testing
- Metoprolol, Losartan
- Where
- Italy
- Volunteers
- 320 people
- Sponsor
- European Institute of Oncology
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Lung Cancer
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00438204
- Testing
- bevacizumab, gemcitabine hydrochloride, pemetrexed disodium
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
This phase II trial studies how well fludeoxyglucose F 18 (FDG)-labeled positron emission tomography (PET) scan works in planning chemotherapy in treating patients with stage IIIB or IV non-small cell lung cancer (NSCLC).
- Conditions
- Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00564733
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Washington
Non-small Cell Lung Cancer (NSCLC)
A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion
The main aim is to evaluate sociodemographic and clinical characteristics of advanced Non-Small Cell Lung Cancer (NSCLC) in adults participants with epidermal growth factor receptor (EGFR) exon 20 insertions mutations during the…
- Trial name
- ermEX-20 (NCT05419700)
- Where
- 15 sites in Spain
- Volunteers
- 76 people
- Sponsor
- Takeda
Lung Cancer, ROS1 Gene Rearrangement
X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement
To assess treatment effectiveness and safety of oral X-396 capsule (Ensartinib) administered to Chinese patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a c-ROS Oncogene (ROS1)…
- Trial name
- NCT03608007
- Testing
- X-396 Capsule
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Thoracic Neoplasms, Non-small Cell Lung Cancer
Postoperative Radiotherapy for Patients With IIIA (N2) Non-small Cell Lung Cancer
Several important international randomized trials have shown that postoperative chemotherapy contributed to the improvement on 5 year survival rate by about 4% for patients with non-small cell lung cancer (NSCLC) after complete…
- Trial name
- NCT00880971
- Testing
- Postoperative 3D-CRT or IMRT
- Where
- China
- Volunteers
- 394 people
- Sponsor
- Chinese Academy of Medical Sciences
Non Small Cell Lung Cancer (NSCLC)
Single Arm on the Tolerability of Weekly Nab-paclitaxel
The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)
- Trial name
- NCT01702844
- Testing
- Nab-Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Cancer
Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Treatment plus supportive care may improve quality of life in patients undergoing cancer treatment.
- Trial name
- NCT00022009
- Testing
- gemcitabine hydrochloride
- Where
- United Kingdom
- Sponsor
- The Christie NHS Foundation Trust
Non-Small Cell Lung Cancer NSCLC
Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of a personalized cancer vaccine alone and in combination with toripalimab in patients with…
- Trial name
- NCT07683832
- Testing
- ABO2109 and toripalimab
- Volunteers
- 50 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Bronchial Neoplasms
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
The aim of this trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D), to define pharmacokinetic (PK) parameters and the preliminary efficacy of a continuous treatment with EGF816 and trametinib…
- Trial name
- EATON (NCT03516214)
- Testing
- EGF816, Trametinib
- Where
- 7 sites in Germany, Spain
- Volunteers
- 18 people
- Sponsor
- University of Cologne
Brain Metastases
Neurocognitive Outcomes In Patients Treated With Radiotherapy For Five Or More Brain Metastases
This is randomized study of neurocognitive outcomes in patients with five or more brain metastases treated with stereotactic radiosurgery (SRS), specifically the Gamma Knife (GK) system, or whole-brain radiation therapy (WBRT).
- Trial name
- NAGKC 12-01 (NCT01731704)
- Testing
- Stereotactic radiosurgery (SRS), Whole brain radiation therapy (WBRT)
- Where
- United States
- Sponsor
- University of California, San Francisco
Non Small Cell Lung Cancer
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine…
- Trial name
- NCT02485652
- Testing
- HM61713
- Where
- 72 sites in United States, Australia and 8 more
- Volunteers
- 162 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Non-small Cell Lung Cancer
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
The purpose of this study is to examine the overall survival of patients with Stage IV non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin and paclitaxel.
- Trial name
- NSCLC (NCT01234038)
- Testing
- ISIS EIF4E Rx, Paclitaxel, Carboplatin
- Where
- 29 sites in United States, Hungary and 2 more
- Volunteers
- 116 people
- Sponsor
- Ionis Pharmaceuticals, Inc.